相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Apixaban: A New Player in the Anticoagulant Class
Ritesh Agrawal et al.
CURRENT DRUG TARGETS (2012)
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review
Donald J. P. Pinto et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects
Yu Chen Barrett et al.
THROMBOSIS AND HAEMOSTASIS (2012)
The Role of Apixaban for Venous and Arterial Thromboembolic Disease
Rathasen Prom et al.
ANNALS OF PHARMACOTHERAPY (2011)
An overview of various validated HPLC and LC-MS/MS methods for quantitation of drugs in bile: challenges and considerations
Nuggehally R. Srinivas et al.
BIOMEDICAL CHROMATOGRAPHY (2011)
Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma
Joseph M. Luettgen et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2011)
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis
Yu Chen Barrett et al.
THROMBOSIS AND HAEMOSTASIS (2011)
LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays
Anne-Francoise Aubry
BIOANALYSIS (2011)
When do you need a validated assay?
Brian Booth
BIOANALYSIS (2011)
Incurred sample reanalysis FOREWORD
Brian Booth
BIOANALYSIS (2011)
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin
Pancras C. Wong et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations
Douglas M. Fast et al.
AAPS Journal (2009)
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Apixaban, an oral, direct and highly selective factor Xa inhibitor:: in vitro, antithrombotic and antihemostatic studies
P. C. Wong et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Donald J. P. Pinto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS
Raymond Naxing Xu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2007)
Orthogonal extraction/chromatography and UPLC, two powerful new techniques for bioanalytical quantitation of desloratadine and 3-hydroxydesloratadine at 25 pg/mL
JX Shen et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2006)
The use of a monolithic column to improve the simultaneous determination of four cephalosporin antibiotics in pharmaceuticals and body fluids by HPLC after solid phase extraction - a comparison with a conventional reversed-phase silica-based column
VF Samanidou et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2004)
Fast HPLC with a silica-based monolithic ODS column
JH Smith et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2003)
分享论文
